Adverse events that were related to NY-ESO-1 TCR-gene transduced T cell infusion (n=9)
| Grade 1–2 | Grade 3 | |
| Any treatment-related adverse events | 7 (77%) | 1 (11%) |
| Interstitial lung disease | 0 | 1 (11%) |
| Cytokine release syndrome | 3 (33%) | 0 |
| Fever | 3 (33%) | 0 |
| Diarrhea | 2 (22%) | 0 |
| Malaise | 2 (22%) | 0 |
| Hypoalbuminemia | 2 (22%) | 0 |
| Anorexia | 1 (11%) | 0 |
| Constipation | 1 (11%) | 0 |
| Hot flush | 1 (11%) | 0 |
| Edema limbs | 1 (11%) | 0 |
| Purpura | 1 (11%) | 0 |
| Tumor pain | 1 (11%) | 0 |
| Tachycardia | 1 (11%) | 0 |
| Platelet count decreased | 1 (11%) | 0 |
| Alanine aminotransferase increased | 1 (11%) | 0 |
| Ferritin increased | 1 (11%) | 0 |
| Fibrinogen decreased | 1 (11%) | 0 |
| Hyperkalemia | 1 (11%) | 0 |
| Hyperuricemia | 1 (11%) | 0 |
| Proteinuria | 1 (11%) | 0 |
| Plasma creatinine increase | 1 (11%) | 0 |
TCR, T cell receptor.